Imaging methods using deuterated compounds
AssigneeGenentech, Inc.
InventorsJan Marik, Joseph P. Lyssikatos, Simon Peter Williams
Life of this patent
Estimating the term…
Abstract
The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
Claims6
A method for detecting one or more of neurofibrillary tangles, senile plaques, or tau protein aggregation in a human subject, the method comprising:
- obtaining a three-dimensional image of the subject's brain;
- administering to the human subject an effective amount of a radiolabeled tracer selected from:
- or a pharmaceutically acceptable salt thereof, wherein the effective amount is sufficient to provide an initial radiation level not greater than 370 MBq;
- acquiring three-dimensional images of the subject's brain with a PET camera at one or more time intervals, thereby providing a 3D PET image of the radioactive signal of the tracer at each of the one or more time intervals;
- aligning the PET images with one another and, using the MR volumetric image for anatomical delineation, identifying irregular regions of interest in the subject's brain;
- measuring the standardized uptake value ratio for each region of interest relative to cerebellum gray at each of the one or more time intervals;
- and
- identifying regions having enhanced standardized uptake value ratios as containing one or more of:
- neurofibrillary tangles, senile plaques, or tau protein aggregation.
A method of detecting a neurological disorder, Alzheimer's disease, or progressive supranuclear palsy in a human subject, the method comprising:
- obtaining a three-dimensional image of the subject's brain;
- administering to the human subject an effective amount of a radiolabeled tracer selected from:
- or a pharmaceutically acceptable salt thereof, wherein the effective amount is sufficient to provide an initial radiation level not greater than 370 MBq;
- acquiring three-dimensional images of the subject's brain with a PET camera at one or more time intervals, thereby providing a 3D PET image of the radioactive signal of the tracer at each of the one or more time intervals;
- aligning the PET images with one another and, using the MR volumetric image for anatomical delineation, identifying irregular regions of interest in the subject's brain;
- measuring the standardized uptake value ratio for each region of interest relative to cerebellum gray at each of the one or more time intervals;
- identifying one or more regions having enhanced standardized uptake value ratios as containing one or more of:
- neurofibrillary tangles, senile plaques, or tau protein aggregation;
- and
- correlating the one or more regions having enhanced standardized uptake value ratios with onset of neurological disorder, Alzheimer's disease, or progressive supranuclear palsy in the subject.
Dependencies are inferred from the claim text.